Next Article in Journal
Molecular Insights to the Structure-Interaction Relationships of Human Proton-Coupled Oligopeptide Transporters (PepTs)
Previous Article in Journal
Recent Advancements in Development and Therapeutic Applications of Genome-Targeting Triplex-Forming Oligonucleotides and Peptide Nucleic Acids
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Zhang et al. Bimodal Imaging of Tumors via Genetically Engineered Escherichia coli. Pharmaceutics 2022, 14, 1804

1
Department of Ultrasound, The Second People’s Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen 518061, China
2
Shantou University Medical College, Shantou 515041, China
3
Center for Cell and Gene Circuit Design, CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
4
Center for Quantitative Synthetic Biology, CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
5
Research Laboratory for Biomedical Optics and Molecular Imaging, CAS Key Laboratory of Health Informatics, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2023, 15(10), 2516; https://doi.org/10.3390/pharmaceutics15102516
Submission received: 6 July 2023 / Accepted: 18 August 2023 / Published: 23 October 2023

Error in Figure

In the original publication [1], there was a mistake in Figure 6. In vivo tracking capability of the tumor-homing characteristic of GVs-miRFP680 MG1655. as published. Due to our carelessness in arranging the images in Figure 6a, the in vivo NIR fluorescent imaging data for the GV MG1655 group at the 0 and 24 h time points (the first two images in the second row) were mistakenly repeated. The corrected Figure 6a appears below. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected.
Pharmaceutics 15 02516 g006

Reference

  1. Zhang, L.; Wang, Y.; Li, D.; Wang, L.; Li, Z.; Yan, F. Bimodal Imaging of Tumors via Genetically Engineered Escherichia coli. Pharmaceutics 2022, 14, 1804. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zhang, L.; Wang, Y.; Li, D.; Wang, L.; Li, Z.; Yan, F. Correction: Zhang et al. Bimodal Imaging of Tumors via Genetically Engineered Escherichia coli. Pharmaceutics 2022, 14, 1804. Pharmaceutics 2023, 15, 2516. https://doi.org/10.3390/pharmaceutics15102516

AMA Style

Zhang L, Wang Y, Li D, Wang L, Li Z, Yan F. Correction: Zhang et al. Bimodal Imaging of Tumors via Genetically Engineered Escherichia coli. Pharmaceutics 2022, 14, 1804. Pharmaceutics. 2023; 15(10):2516. https://doi.org/10.3390/pharmaceutics15102516

Chicago/Turabian Style

Zhang, Linlin, Yuanyuan Wang, Dengjin Li, Liang Wang, Zhenzhou Li, and Fei Yan. 2023. "Correction: Zhang et al. Bimodal Imaging of Tumors via Genetically Engineered Escherichia coli. Pharmaceutics 2022, 14, 1804" Pharmaceutics 15, no. 10: 2516. https://doi.org/10.3390/pharmaceutics15102516

APA Style

Zhang, L., Wang, Y., Li, D., Wang, L., Li, Z., & Yan, F. (2023). Correction: Zhang et al. Bimodal Imaging of Tumors via Genetically Engineered Escherichia coli. Pharmaceutics 2022, 14, 1804. Pharmaceutics, 15(10), 2516. https://doi.org/10.3390/pharmaceutics15102516

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop